



## Aerie Pharmaceuticals to Present at the Cantor Fitzgerald 2018 Global Healthcare Conference

September 25, 2018

DURHAM, N.C.--(BUSINESS WIRE)--Sep. 25, 2018-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other diseases of the eye, today announced that Richard Rubino, Chief Financial Officer, will present at the Cantor Fitzgerald 2018 Global Healthcare Conference on Tuesday, October 2, 2018 at 2:15 p.m. Eastern Time in New York, NY. Mr. Rubino will provide an Aerie overview and business update.

The presentation will be webcast live and may be accessed by visiting Aerie's website at <http://investors.aeriepharma.com/>. A replay of the webcast will be available for 10 business days.

### About Aerie Pharmaceuticals, Inc.

Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other diseases of the eye. Aerie's first product, Rhopressa® (netarsudil ophthalmic solution) 0.02%, a once-daily eyedrop approved by the U.S. Food and Drug Administration (FDA) for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, was launched in the United States in April 2018. In clinical trials of Rhopressa®, the most common adverse reactions were conjunctival hyperemia, cornea verticillata, instillation site pain, and conjunctival hemorrhage. More information about Rhopressa®, including the product label, is available at [www.rhopressa.com](http://www.rhopressa.com). Aerie's advanced-stage product candidate, Roclatan™ (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%, a fixed-dose combination of Rhopressa® and the widely-prescribed PGA (prostaglandin analog) latanoprost, achieved its 3-month primary efficacy endpoint in two Phase 3 registration trials, Mercury 1 and Mercury 2, and also showed safety and efficacy throughout 12 months in Mercury 1. Aerie submitted the Roclatan™ New Drug Application (NDA) in May 2018 and, in July 2018, the FDA set the PDUFA (Prescription Drug User Fee Act) goal date for the completion of the FDA's review of the Roclatan™ NDA for March 14, 2019. Aerie continues to focus on global expansion and the development of additional product candidates and technologies in ophthalmology, including for wet age-related macular degeneration and diabetic macular edema. More information is available at [www.aeriepharma.com](http://www.aeriepharma.com).

View source version on businesswire.com: <https://www.businesswire.com/news/home/20180925005002/en/>

Source: Aerie Pharmaceuticals, Inc.

Aerie Pharmaceuticals

Media:

Tad Heitmann, 949-526-8747

[theitmann@aeriepharma.com](mailto:theitmann@aeriepharma.com)

or

Investors:

Richard Rubino, 908-947-3540

[rrubino@aeriepharma.com](mailto:rrubino@aeriepharma.com)

or

Burns McClellan, Inc., on behalf of Aerie Pharmaceuticals

Investors:

Ami Bavishi, 212-213-0006

[abavishi@burnsmc.com](mailto:abavishi@burnsmc.com)